[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600595":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":27,"responsibleParty":44,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IV Ketamine Double Infusion (0.5 mg\u002Fkg) for Severe Borderline Personality Disorder","EXPERIMENTAL",null,[13],"Drug: IV Ketamine (0.5 mg\u002Fkg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","IV Ketamine (0.5 mg\u002Fkg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder","Participants receive two intravenous (IV) infusions of ketamine at a dose of 0.5 mg\u002Fkg over 40 minutes. The first infusion is administered at Hour 0 (H0) and the second at Hour 24 (H24). Vital signs and potential adverse effects are closely monitored before, during, and after each infusion. This intervention aims to assess the short-term efficacy and safety of ketamine in reducing symptoms of severe borderline personality disorder.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Gaël Galliot","CONTACT","+33 (0)5 34 55 76 51","33","galliot.g@chu-toulouse.fr",[28],{"facility":29,"status":11,"city":30,"state":11,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Toulouse Purpan University Hospital, Head of Psychiatry Clinic in the UF3 department","Toulouse","31059","France","FR",{"type":35,"coordinates":36},"Point",[37,38],1.44367,43.60426,{"lat":38,"lon":37},[41,42],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},{"name":22,"role":43,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100600595",false,"NCT07099534","Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder","Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder: A Pilot Study","BorderKET","Inclusion Criteria:\n\n* Adult patient aged 18 to 65 years\n* Fluent in French\n* Person affiliated with or receiving social security benefits.\n* Diagnosis of borderline personality disorder established according to the DSM-5 MINI criteria (5 out of 9 criteria)\n* Severe borderline personality disorder\n* Patient receiving stable pharmacological (antipsychotic, mood stabilizer, antidepressant) and\u002For non-pharmacological (schema therapy, DBT) treatment for four weeks\n\nExclusion Criteria:\n\n* Personal history of an acute psychotic episode or chronic psychotic disorder\n* Personal history of a manic or hypomanic episode\n* Family history (first-degree relatives) of a psychotic disorder\n* Current severe depressive episode\n* Recreational ketamine use (multi-weekly ketamine use)\n* New long-term treatment introduced within the previous four weeks (antidepressant, antipsychotic, mood stabilizer)\n* Prescription of an Monoamine oxidase inhibitors (increased risk of hypertension)\n* Specific absolute contraindication to ketamine\n* History of cirrhosis or major liver function test abnormalities\n* Major ECG abnormality","ALL","18 Years","65 Years",{"count":57,"type":58},38,"ESTIMATED","INTERVENTIONAL",[61],"PHASE2","The main objective of this pilot study is to evaluate at D9 the evolution of BPD symptoms' intensity(scale BSL-23) in severe BPD patients, after two Ketamine infusions (0.5mg\u002Fkg at H0 and H24). The intervention is combined with the first level standard of care : Good Psychiatric Management (GPM). Patients are followed up to 3 months by regular visits conducted by a psychiatrist. Secondary outcomes are monitored including BPD symptoms at different times, suicidal ideation, depressiv symptoms, healthcare use and adverse effects.",[64,65],"Infusion of Ketamine in Severe Borderline Personality Disorder","Borderline Personality Disorder (BPD)",[67,68,69],"Ketamine","borderline personality disorder","BDP","NOT_YET_RECRUITING","2026-05-07",{"date":73,"type":74},"2026-05-12","ACTUAL",{"date":76,"type":58},"2026-09-01",{"date":78,"type":58},"2028-09-30",{"name":5,"class":6},1]